We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline.
Y Combinator, The Clermont Group, Breyer Capital, Lifeforce Capital, I2BF Global Ventures, Metaplanet, HOF Capital, Ace & Company, Pioneer Fund
Company Traction
In May 2022, PostEra announced a $68 million partnership with the National Institutes of Health to develop antiviral therapeutics.
In January 2022, PostEra announced a partnership with Pfizer to advance multiple drug discovery programs with a total contract value of $260 million if they accomplish all milestones.
Leadership Team
Aaron Morris: Co-Founder & CEO of PostEra. Former Equities Trading, Event-Driven Quant at Goldman Sachs.
Alpha Lee: Co-Founder & Chief Scientific Officer of PostEra. Co-Founder of Byterat.
Marie-Laure Rives: Head of Biology at PostEra. Former Director of Molecular and Cellular Pharmacology at Ferring Pharmaceuticals.
Emily Ripka: Head of Product at PostEra. Former Research Scientist at Canon.
Tony S.: Head of Machine Learning at PostEra. Former Senior Data Scientist at Nielsen.
